Immunotherapy is becoming recognized as a superior treatment for cancer. In recent years, chimeric antigen receptor (CAR) therapy is among the immunotherapies that has had growing success rates. CAR T-cell therapy takes patient’s T-cells and encodes them with a CAR expressing gene, which can then target their cancer cells. However, there are some dangers associated with this therapy. If a cancer cell is mistakenly transfected with the CAR molecule, it can become resistant to the therapy. Using the electric properties of the cells, we have created a technique that can purify the T-cells from the remaining cancer cells using microfluidics and dielectrophoresis (DEP). Then, to further improve the therapy, the sample is electroporated following being patterned using DEP forces, which transfects the cells without using viral vectors and provides longer CD19 expression.